Small vessel disease is a condition causing blood vessel dysfunction that occurs with aging and contributes to the development of cardiovascular disease, dementia, and stroke. As a consequence of the profound effects of small vessel disease on the functioning of the brain and blood-brain barrier, for the purposes of this article, we will focus predominantly on cerebral aspects of small vessel disease, called cerebral small vessel disease.

Small vessel disease in the brain contributes to approximately 50 percent of dementia cases worldwide, including Alzheimer's disease, Parkinson's disease, and other common neurodegenerative diseases.[1][2]

Brain and vascular phenomena of small vessel disease

The functional impact of cerebral small vessel disease on cognition can be predicted through a system of scoring medical images to observe contributing phenomena directly. [3] The contributing phenomena attributed to cognitive decline as a result of small vessel disease include:

  • White Matter Hyperintensities - Areas of white matter lesions that appear bright white on an MRI scan. The development of white matter hyperintensities may be mediated by cumulative exposure to hypertension (i.e., high blood pressure)[4] and contributes to cognitive decline and dementia.[5]
  • Cerebral Microbleeds - Small deposits of blood waste products (mainly hemosiderin) that accumulate when blood escapes from nearby damaged small vessels, as called a hemorrhage. Age and hypertension contribute to the formation of cerebral microbleeds.[6]
  • Lacunes (from the Latin for "little lakes") - Areas of empty space on an MRI scan where chronic ischemia (inadequate blood flow) has resulted in tissue death, often following chronic cerebral microbleeds. Increased burden of lacunes is associated with cognitive decline and gait disturbances in older adults.[7]
  • Enlarged Perivascular Spaces - A build-up of interstitial fluid that is unable to be exchanged with fresh serum flowing through adjacent blood vessels. Enlarged perivascular spaces compromise waste removal by the glymphatic system, increasing brain concentrations of toxins, such as amyloid-beta, which contributes to the development of Alzheimer's disease.[8]
  • Brain Atrophy - A loss of tissue mass that occurs when the brain must downsize the number of neurons and neuronal connections it supports due to chronic deprivation of nutrients and growth factors and accumulation of waste. Brain atrophy can be measured in midlife prior to the development of cognitive impairments and is more pronounced in adults with obesity compared to adults with a lean BMI.[9]

Prevention at a glance

There are a variety of lifestyle behaviors and risk factors that may affect the development of cerebral small vessel disease or pathologies associated with the disease, including:

  • Aerobic exercise reduced the risk of dementia and cognitive impairment due to increased production of brain-derived neurotrophic factor (BDNF), which encourages plasticity and preserves synaptic density. Exercise also reduced the burden of lacunes, white matter hyperintensities, and other markers of small vessel disease.[10]
  • Low levels of plasma omega-3 polyunsaturated fatty acids were associated with more severe cerebral small vessel diseases in patients who had experienced an ischemic stroke.[11]
  • Participants with the highest serum concentration of vitamin D had fewer white matter hyperintensities, enlarged perivascular spaces, and total burden of small vessel disease.[12]
  • Greater visceral abdominal fat was independently associated with increased markers of cerebral small vessel disease in participants without a history of symptomatic cerebrovascular disease. [13]
  • Patients with hypertension have a greater burden of cerebral small vessel disease and are at greater risk of cognitive impairment, especially when presenting with progressive white matter hyperintensities.[14]

Small vessels are one half of the blood-brain barrier

The blood-brain barrier separates the central nervous system (CNS) and the peripheral circulatory system, tightly controlling what substances pass into or out of the brain; this function (controlling what substances pass into or out of the brain) relies on the integrity small vessels at the blood-brain barrier. The vascular half of the blood-brain barrier is composed of small vessel endothelial cells and pericytes, which are multipurpose cells that control the dilation and constriction of blood vessels.[15] Both types of cells, while present throughout the body, have special characteristics at the blood-brain barrier that critically links small vessel health to broader brain health.

Endothelial cells connect to each other using tight-junction proteins, which can be modified in shape to suit the needs of different tissues in the body. In tissues responsible for the filtering of waste, such as the kidneys and liver, loose tight junctions allow for increased paracellular transport. This mode of nutrient and waste exchange occurs when substances from the blood seep through vessel walls instead of being transported intracellularly using membrane transporters with high selectivity. Tight junctions connecting endothelial cells at the blood-brain barrier form much tighter junctions than those of the liver and take on a structure more similar to epithelial tissue (e.g., skin), which severely limits paracellular transport.[16]

The ratio of endothelial cells to pericytes also varies among the small vessels of the body with the microvasculature of the CNS having the highest proportion of pericytes. Compared to small vessels in the lungs (10:1 ratio of endothelial cells to pericytes), which form a more permeable barrier than the brain, and skeletal muscle (100:1 ratio of endothelial cells to pericytes), which has little barrier capacity, small vessels of the brain form the most restrictive barrier with approximately a 1:1 ratio of endothelial cells to pericytes.[17]

These perciytes strengthen small vessel integrity by controlling vessel dilation, providing trophic support to endothelial cells (e.g., encouraging endothelial cell proliferation and differentiation), and secreting components of the extracellular matrix that connect small vessels to astroglia.[18] These star-shaped cells form the central nervous system half of the blood-brain barrier, bridging the distance between blood vessels and neurons, while selectively choosing which substances come into contact with neurons. The multicellular structures formed by endothelial cells, pericytes, and atroglia contain many sets of connecting membranes and are called a neurovascular unit. These structures serve the purpose of nutrient and waste exchange for neurons while providing many points of regulation to prevent neuronal damage.[15]

Endothelial dysfunction compromises the blood-brain barrier

Endothelial dysfunction compromises the integrity of neurovascular units, increasing the concentration of toxins and pathogens in the brain and accelerating brain aging.[19]

Endothelial cells line blood vessels throughout the body and require a lot of energy to regulate vascular tone efficiently.[20] Endothelial dysfunction can be caused by hyperglycemia and oxidative stress, which reduces the number of endothelial progenitor cells over time, worsening small vessel disease. Dysfunctional epithelial cells promote blood vessel rigidity, inflammation, and excessive clotting, contributing to cardiovascular and neurodegenerative disease progression.[21]

The mechanisms underlying endothelial dysfunction have yet to be fully elucidated; however, inflammation, a key regulator of blood vessel permeability, is a major contributor. Chronic inflammation caused by lack of micronutrients is common in aging. For example, high levels of serum homocysteine, a byproduct of normal cellular metabolism that is an endothelial toxin at high concentrations, can be caused by vitamin B12 deficiency, a common problem in older adults.[22] Hyperhomocysteinemia is common in individuals with small vessel disease[3] and increases in severity as small vessel disease worsens.

Endothelial dysfunction increases with age and contributes to inflammaging, a process of tissue degeneration characterized by altered cellular senescence, immunosenescence, mitochondrial dysfunction, defective autophagy, metabolic inflammation, and gut microbiota dysbiosis.[23] Chronic inflammation and tissue injury at the BBB increases the risk of autoimmunity and neurodegeneration as immune cells encounter damage-associated molecular patterns and risk producing antibodies against self-antigens released from damaged CNS tissues.[3]

Blood-brain barrier leakage is a consequence of small vessel disease

Many of the observable cerebral phenomena of small vessel disease, such as white matter hyperintensities and lacunar strokes, are predictive of the amount and degree of blood-brain barrier leakage.[3]

Permeability of the blood-brain barrier, is partially regulated by tight-junction proteins, which form attachments between the cytoskeletons of adjacent cells. High serum phosphate levels, which are common in people with cerebral small vessel disease, downregulate the assembly of tight junction proteins, increasing BBB permeability. Severe vitamin D deficiency increases serum phosphate levels by reducing phosphate excretion by the kidneys[24] and is more common in individuals with severe small vessel disease.[12]

Permeability of the blood-brain barrier is also modulated by the types of lipids used to create neurovascular membranes. For example, unsaturated fats make membranes less compact and more fluid, while saturated fats create rigid membranes that are less efficient at nutrient and waste exchange.[25] Increased permeability of neurovascular units allows endotoxins and inflammatory immune cells to infiltrate the brain, contributing to brain aging.[26]

A leaky blood-brain barrier reduces perfusion and impairs cognition

"Older adults with early cognitive dysfunction display blood-brain barrier leakage in the hippocampus regardless of the deposition of amyloid or tau, demonstrating the importance of vascular markers in the early diagnosis of dementia. 10.1016/j.jalz.2018.07.222" Click To Tweet

Chronic hyperpermeability of the BBB leads to adaptations such as an increased thickness and disorganization of blood vessels, which reduces perfusion, the passage of blood from cardiovascular circulation into tissues, delivering nutrients and diluting waste.[27] Hypoperfusion, a defining characteristic of small vessel disease, deprives tissues of oxygen, causing mitochondrial dysfunction and increasing oxidative stress.[28] Compared to older adults without small vessel disease, patients with overt cerebral small vessel disease had a greater volume of white and grey matter with subtle signs of blood-brain barrier leakage and reduced perfusion and cerebral blood volume.[29]

Hypoperfusion initiates a vicious cycle of nutrient deprivation, metabolic stress, inflammation, and waste accumulation that is central to cognitive impairment. While dementias such as Alzheimer's disease are often diagnosed based on the visual appearance of amyloid-beta plaques and phosphorylated-tau tangles, blood-brain barrier leakage and vascular dysfunction often precede the appearance of amyloid and tau deposits. Older adults with early cognitive dysfunction display blood-brain barrier leakage in the hippocampus regardless of the deposition of amyloid or tau, demonstrating the importance of vascular markers in the early diagnosis of dementia.[1] Intervening in dementia by alleviating the endothelial dysfunction and hypoperfusion associated with small vessel disease may be a more effective strategy than focusing on amyloid-beta removal, as earlier dementia research has done.[30]

Glymphatic dysfunction impairs waste disposal

Impaired glymphatic function, a feature of small vessel disease, contributes to brain injury and presents as an enlargement of perivascular space.

The glymphatic system circulates interstitial fluid in the brain in an avascular manner, meaning neither blood nor lymph vessels are required for fluid movement. Interstitial fluid is exchanged with fresh plasma, which perfuses from nearby blood vessels. This system of highly controlled fluid movement is responsible for waste disposal during sleep, injury, and illness because, unlike other organs, the brain has no traditional lymphatic structures.[31] Glymphatic dysfunction disturbs normal pressure in the brain and impairs waste disposal, contributing to neurodegeneration.[32]

Using gadolinium-based MRI dye, researchers can measure the rate of fluid exchange in perivascular spaces at the blood-brain barrier. Estimated glymphatic clearance rate is inversely related to cerebral small vessel disease, meaning that as the burden of small vessel disease markers increases, the ability of the glymphatic system to circulate fluid decreases. Impaired exchange of fluids at the blood-brain barrier increases the occurrence of enlarged perivascular spaces, where stagnant interstitial fluid accumulates toxins that injure the brain.[3]

Enlarged perivascular spaces

Enlarged perivascular spaces are a feature of neurodegeneration and are associated with other markers of small vessel disease, such as white matter hyperintensities, and other signs of brain disease such as chronic inflammation and blood-brain barrier dysfunction.

Perivascular spaces are fluid-filled spaces that form around blood vessels in several organs including the brain that participate in normal nutrient and waste exchange. These spaces are filled with interstitial fluid that seeps into the space due to increased blood vessel permeability. Perivascular spaces are common in the body and may have an immunological function, as increased blood vessel permeability facilitates diapedesis, the movement of white blood cells from the bloodstream into tissues.[33] Enlarged perivascular spaces are commonly found in healthy adults in small number; however, an increased occurrence of enlarged perivascular spaces in the brain is associated with aging,[34] depression,[35] cognitive decline,[36] and diabetes.[37]

As a result of perivascular enlargement, the efficiency of fluid exchange at the BBB is reduced, resulting in the accumulation of misfolded proteins such as amyloid-beta, which contributes to Alzheimer's pathology,[3] and alpha-synuclein, which contributes to Parkinson's pathology.[38] The accumulation of toxins is greatest when fluid exchange is disrupted during sleep, a time when the brain cleans out toxins that build up during the day from normal metabolism and harmful environmental exposures. During sleep, fluid volume in the brain increases to dilute waste and exchange cerebrospinal fluid with plasma from the bloodstream.[3] Enlarged perivascular spaces and poor sleep are both common in people with Alzheimer's disease and other neurodegenerative diseases. Interventions that increase sleep duration, such as short daily naps, and sleep quality, such as light exercise, have demonstrated efficacy in alleviating symptoms of Alzheimer's disease.[39]

Deeper damage in the brain

Over time, hypoxia, reduced delivery of nutrients and growth factors, accumulation of toxins and dysfunctional proteins, and chronic inflammation leads to long-term structural changes in the brain that are visible using medical imaging and include white matter hyperintensities, occluded vessels, cerebral microbleeds, lacunes, enlarged perivascular spaces, and brain atrophy — the defining cerebral traits of small vessel disease.

White matter hyperintensities

Tissues in the CNS are characterized as gray matter, which are areas in the brain, brainstem, and cerebellum where neuron bodies are concentrated, or white matter, which are bundles of axon fibers that form connections among neurons. White matter appears white in tissue samples compared to gray matter due to an increased concentration of lipids, which form the insulating myelin sheaths around axon fibers. Gray matter is concentrated in the cerebral cortex, the outermost layer of brain tissue, with white matter positioned under this layer, deeper in the brain. White matter is highly vascularized and vulnerable to ischemia (i.e., reduced blood flow) due to its deep location.

White matter hyperintensities are lesions found in white matter that appear bright white on a magnetic resonance imaging (MRI) scan because the area has a decreased density of axons and blood vessels.[40] Often, this reduced cell density is the result of hypoxia and cell death.[41] White matter hyperintensities of vascular origin are also referred to as leukoaraiosis.[42]

Studies utilizing diffusion tensor imaging, a sophisticated type of MRI that measures the movement of water in white matter,[43] have detected white matter dysfunction that precedes the visual appearance of white matter hyperintensities, suggesting that white matter hyperintensities are the final stage of a pathological process that involves long-term small vessel disease.[5] White matter hyperintensities increase with age, hypertension,[5] and obesity[44] and are associated with depression,[45] cognitive impairment, and physical disability.[5] The association between white matter hyperintensities and disease follows a stepwise pattern, meaning the more lesions that are visible, the greater the risk of impairment. This relationship is especially strong when lesions are confluent, so that larger continuous areas of white matter die, disrupting communication between different hubs of gray matter neurons.[5]

Contributions to functional impairments in neurodegenerative diseases

Neurodegenerative diseases include hundreds of distinct illnesses that present with specific sets of symptoms based on the location of brain lesions such as the cerebral cortex, basal ganglia, brainstem and cerebellum, and spinal cord. Degeneration in the cerebral cortex causes dementia and Alzheimer's disease. Lesions located in the basal ganglia result in movement disorders such as Parkinson's disease. Small vessel disease leads to hypoperfusion and hypoxia in the brain, causing protein misfolding and downstream endothelial dysfunction, BBB break-down, and inflammation.[46]

Alzheimer's disease

"Newer research finds that small vessel disease burden has a greater effect on cognition in those with dementia than amyloid-beta and tau burden, demonstrating a shift in how scientists and clinicians should research and diagnose Alzheimer's disease. 10.1016/j.conb.2020.02.003'" Click To Tweet

Alzheimer's disease is a type of dementia that presents with plaques of misfolded amyloid-beta and phosphorylated tau proteins in the brain. While early research of Alzheimer's disease implicated these proteins as a cause of the disease, recent research suggests misfolded proteins accumulate secondary to metabolic disease, small vessel disease, and chronic inflammation.[47] Therapies that target the removal of misfolded proteins have been largely unsuccessful in reducing Alzheimer's disease severity, revealing the need for therapies upstream of protein misfolding.[47]​​ Newer research finds that small vessel disease burden has a greater effect on cognition in those with dementia than amyloid-beta and tau burden, demonstrating a shift in how scientists and clinicians should research and diagnose Alzheimer's disease.[1]

Maintaining the lipid membranes that comprise the blood-brain barrier may be an important area for intervention, as older adults with greater serum concentration of small high-density lipoprotein (HDL) particles and cerebrospinal fluid concentrations of the lipids phosphatidylcholine, sphingomyelin, and lysophosphatidylcholine had less amyloid-beta. Small HDL particles remove oxidized lipids from endothelial cells at the BBB, reducing inflammation, small vessel dysfunction, and amyloid-beta deposition.[48] Strategies for increasing small HDL particle number include pharmaceutical drugs and exercise. In one study, four weeks of daily supplementation with four grams of the omega-3's eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) combined with exercise had a uniquely powerful effect on raising small HDL levels.[49] A growing body of evidence suggests that omega-3 intake during the early stages of Alzheimer's disease may reduce disease severity.[50]

Parkinson's disease

Parkinson's disease is characterized by motor neuron dysfunction, resulting in tremors, muscle rigidity, and movement difficulties. However, some people with the disease may also experience depression and cognitive impairment.[2] The brains of people with Parkinson's disease display multiple markers of cerebral small vessel disease. One study with more than 100 Parkinson's disease patients found lacunes in 9 percent of the patients, deep white matter hyperintensities in 81 percent, enlarged perivascular spaces in 85 percent, and cerebral microbleeds in 3 percent. A greater burden of small vessel disease markers was related to greater disease severity.[51]

Neuroinflammation is a driver of cerebral small vessel disease and early neuron dysfunction in Parkinson's disease. The transcription factor NFkB activates the expression of pro-inflammatory genes, and its activity is increased in Parkinson's disease. Polyphenols from foods such as berries, greens, and tea inhibit the NFkB inflammatory pathway and, therefore, may reduce Parkinson's disease risk.[52] In studies with mice, polyphenol treatments reduce inflammation and oxidative stress and protect dopaminergic neurons.[53] Human trials demonstrate that a diet rich in polyphenols improves small vessel function[54] and robustly improves executive function, language, attention, concentration, and active memory in people with Parkinson's disease.[55]

Topics

  • Blood-brain barrier - Small vessels are one half of the blood-brain barrier, the multicellular membranes that separate the central nervous system from the bloodstream. Small vessel disease is intimately related to blood-brain barrier dysfunction.

Episodes

Small vessel disease FAQ's

Q: What is the overall prevalence of cerebral small vessel disease?

A: The prevalence of cerebral small vessel diseases increases with age, affecting about 5 percent of people aged 50 years and older and nearly 100 percent of people older than 90 years and causing an estimated 25 percent of strokes.[56]

Q: How can clinicians track or diagnose small vessel disease and/or the permeability of the blood-brain barrier?

A: Currently, there are no clinically-approved methods for measuring blood-brain barrier permeability. However, research methods exist that use a standard 15-minute MRI with an injection of a gadolinium tracer that helps to visualize the severity of blood-brain barrier leakiness. With aging, the hippocampus, medial temporal lobe, and the caudate nucleus are specific brain areas where barrier dysfunction is concentrated and this is represented by a leaking of the gadolinium tracer into deeper brain tissue.

Researchers at the University of Southern California are currently investigating other potential ways to track cerebral small vessel disease with varying degrees of invasiveness. For example, soluble platelet-derived growth factor-beta receptor is a protein released from damaged pericytes that can be measured in plasma from a standard blood draw. Other techniques rely on analysis of cerebrospinal fluid. Hopefully, these and other research methods could be approved for clinical practice in diagnosing dementia early in the disease process.

Q: What exercise activities may be best suited to reducing the risk of cerebral small vessel disease?

A: Improving cardiovascular fitness, especially with the aim of better management of blood pressure and reducing the pathological processes contributing to the production of white-matter hyperintensities, may be a particularly high-leverage prevention activity. ​​In one study with middle-aged and older adults without cognitive impairment, hypertension was associated with accelerated brain aging in a dose-dependent manner. For every 10 mmHG increase in blood pressure (systolic or diastolic), estimated brain age increased by about 65 days.[57] Hypertension may be even riskier for people with an apolipoprotein E4 allele, a genetic variant that increases Alzheimer's disease risk, because it increases the amount of amyloid-beta deposition in the brain.[58]

In another study supporting the role of hypertension in small vessel disease and dementia, elevated blood pressure in midlife increased the burden of white matter hyperintensities in the brain.[4] Maintaining a systolic blood pressure of less than 120 mmHG may be optimal for reducing the risk of cerebral small vessel disease and dementia.[59] Aerobic exercise, in particular, helps maintain healthy blood pressure. For example, one study showed that men who completed a 12-week exercise program that included 40 to 60 minutes of walking or jogging one to three days per week reduced their systolic blood pressure by 15 mmHg and diastolic pressure by 10 mmHg.

Q: What foods or nutrients may be helpful in reducing the risk of cerebral small vessel disease?

A: The marine omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) profoundly affect brain health. The brain accumulates DHA in its cellular membranes more than any other organ in the body. To do this, it uses a transporter called Mfsd2a. Because DHA has a long and irregular shape, it increases membrane fluidity while also restricting transport across membranes.[60]

These qualities make DHA well suited for the needs of the blood-brain barrier. Illustrative of the functional importance of omega-3 DHA in the healthy maintenance of the blood-brain barrier, blocking the transport of DHA has been investigated in the lab as a drug action that temporarily permeabilizing the brain-brain barrier for specialized purpose (e.g., enhancing brain drug delivery of chemotherapeutics).[61]

Common dietary sources of EPA and DHA include seafood and fish (salmon, mackerel, anchovies, sardines, and herring are particularly dense sources), but can also be found in microalgae. Fish and seafood provide omega-3s in long-chain form, which are used by the body differently from plant sources of omega-3s.Learn about this specialized role of omega-3 DHA in our overview of the blood-brain barrier here.

Polyphenols, a large class of bioactive plant compounds found in foods such as berries and green tea, have also notably been shown to improve endothelial function.[62] In one study involving participants with white matter hyperintensities, a supplement containing apple and apple polyphenols, lemon balm, ginger, choline, and vitamin B6 reduced markers of oxidative stress and reduced dizziness and disability.[63]

Diets that minimize salt and sugar intake have a demonstrated relationship with lower small vessel disease risk. Among individuals who had experienced a stroke, a dietary history that minimized salt intake was protective against signs of small vessel disease.[64] In another study with individuals who had experienced a stroke, a lower current intake of high glycemic foods was associated with reduced small vessel disease burden.[65]

Q: How does the gut microbiota contribute to small vessel disease?

Among participants without a history of dementia or stroke, an enterotype (i.e., broad categorization of the types of bacteria that predominate in the microbiota) predominated by the genera Bacteroides was associated with more signs of cerebral small vessel disease, cognitive decline, and behavioral and psychological symptoms.[66] In another study, depletion of beneficial microbes that strengthen the gut barrier, such as Akkermansia muciniphila, increases blood pressure and small vessel disease burden.[67]

Previous research demonstrates that a Western diet pattern, heavy in animal fat and protein, shifts the gut microbiota toward the Bacteroides enterotype, while a diet high in fiber-rich plant foods shifts the microbiota toward an enterotype predominated by the genus Prevotella.[68] Among patients with Parkinson's disease, an enterotype predominated by Bacteroides was associated with a reduced concentration of barrier-strengthening fecal short-chain fatty acids (e.g., butyrate) and increased concentration of fecal calprotectin, a marker of intestinal inflammation, and zonulin, a tight-junction protein and marker of intestinal barrier dysfunction.[69]

  1. ^ a   b   c Vascular dysfunction The disregarded partner of Alzheimer s disease Alzheimer s &thsemicolon Dementia 15, no. 1 (January 2019): 158–67. https://doi.org/10.1016/j.jalz.2018.07.222.
  2. ^ a   b Exploring the association between Cerebral small-vessel diseases and motor symptoms in Parkinson s disease Brain and Behavior 9, no. 4 (February 2019): e01219. https://doi.org/10.1002/brb3.1219.
  3. ^ a   b   c   d   e   f   g Understanding the role of the perivascular space in cerebral small vessel disease Cardiovascular Research 114, no. 11 (May 2018): 1462–73. https://doi.org/10.1093/cvr/cvy113.
  4. ^ a   b Midlife blood pressure is associated with the severity of white matter hyperintensities: analysis of the UK Biobank cohort study European Heart Journal 42, no. 7 (November 2020): 750–57. https://doi.org/10.1093/eurheartj/ehaa756.
  5. ^ a   b   c   d   e White matter hyperintensities, cognitive impairment and dementia: an update Nature Reviews Neurology 11, no. 3 (February 2015): 157–65. https://doi.org/10.1038/nrneurol.2015.10.
  6. ^ Cerebral microbleeds: overview and implications in cognitive impairment Alzheimer s Research &thsemicolon Therapy 6, no. 3 (2014): 33. https://doi.org/10.1186/alzrt263.
  7. ^ DOI: ​​10.1177/0271678X20908361
  8. ^ Perivascular spaces in the brain: anatomy, physiology and pathology Nature Reviews Neurology 16, no. 3 (February 2020): 137–53. https://doi.org/10.1038/s41582-020-0312-z.
  9. ^ Obesity associated with increased brain age from midlife Neurobiology of Aging 47 (November 2016): 63–70. https://doi.org/10.1016/j.neurobiolaging.2016.07.010.
  10. ^ Physical Exercise as a Preventive or Disease-Modifying Treatment of Dementia and Brain Aging Mayo Clinic Proceedings 86, no. 9 (September 2011): 876–84. https://doi.org/10.4065/mcp.2011.0252.
  11. ^ Low levels of plasma omega 3-polyunsaturated fatty acids are associated with cerebral small vessel diseases in acute ischemic stroke patients Nutrition Research 35, no. 5 (May 2015): 368–74. https://doi.org/10.1016/j.nutres.2015.04.008.
  12. ^ a   b 25-Hydroxy vitamin D level is associated with total MRI burden of cerebral small vessel disease in ischemic stroke patients International Journal of Neuroscience 129, no. 1 (November 2018): 49–54. https://doi.org/10.1080/00207454.2018.1503182.
  13. ^ Visceral fat accumulation is associated with cerebral small vessel disease European Journal of Neurology 21, no. 4 (February 2014): 667–73. https://doi.org/10.1111/ene.12374.
  14. ^ Cognitive Impact of Cerebral Small Vessel Disease Changes in Patients With Hypertension Hypertension 73, no. 2 (February 2019): 342–49. https://doi.org/10.1161/hypertensionaha.118.12090.
  15. ^ a   b The Neurovascular Unit Coming of Age: A Journey through Neurovascular Coupling in Health and Disease Neuron 96, no. 1 (September 2017): 17–42. https://doi.org/10.1016/j.neuron.2017.07.030.
  16. ^ Kniesel, Uwe, and Hartwig Wolburg. Cellular and Molecular Neurobiology 20, no. 1 (2000): 57–76. https://doi.org/10.1023/a:1006995910836.
  17. ^ Pericyte physiology The FASEB Journal 7, no. 11 (August 1993): 1031–38. https://doi.org/10.1096/fasebj.7.11.8370472.
  18. ^ The Blood Brain Barrier Cold Spring Harbor Perspectives in Biology 7, no. 1 (January 2015): a020412. https://doi.org/10.1101/cshperspect.a020412.
  19. ^ <thsemicolonp>thsemicolonSmall vessel disease to subcortical dementia: a dynamic model, which interfaces aging, cholinergic dysregulation and the neurovascular unit<thsemicolon/p>thsemicolon Vascular Health and Risk Management Volume 15 (August 2019): 259–81. https://doi.org/10.2147/vhrm.s190470.
  20. ^ DOI: ​​10.1101/2021.09.14.460297
  21. ^ Endothelial Dysfunction Journal of the American Society of Nephrology 15, no. 8 (August 2004): 1983–92. https://doi.org/10.1097/01.asn.0000132474.50966.da.
  22. ^ Vitamin B12 deficiency Nature Reviews Disease Primers 3, no. 1 (June 2017). https://doi.org/10.1038/nrdp.2017.40.
  23. ^ Age-related cerebral small vessel disease and inflammaging Cell Death &thsemicolon Disease 11, no. 10 (October 2020). https://doi.org/10.1038/s41419-020-03137-x.
  24. ^ High Circulatory Phosphate Level Is Associated with Cerebral Small-Vessel Diseases Translational Stroke Research 10, no. 3 (June 2018): 265–72. https://doi.org/10.1007/s12975-018-0639-6.
  25. ^ Decreased membrane fluidity and altered susceptibility to peroxidation and lipid composition in overweight and obese female erythrocytes Journal of Lipid Research 45, no. 10 (October 2004): 1846–51. https://doi.org/10.1194/jlr.m300509-jlr200.
  26. ^ Role of the Blood-Brain Barrier in the Pathogenesis of Alzheimers Disease Current Alzheimer Research 4, no. 2 (April 2007): 191–97. https://doi.org/10.2174/156720507780362245.
  27. ^ Blood-brain barrier and cerebral small vessel disease Journal of the Neurological Sciences 299, no. 1-2 (December 2010): 66–71. https://doi.org/10.1016/j.jns.2010.08.042.
  28. ^ Cerebral Small Vessel Disease Cell Transplantation 27, no. 12 (September 2018): 1711–22. https://doi.org/10.1177/0963689718795148.
  29. ^ Blood brain barrier leakage is more widespread in patients with cerebral small vessel disease Neurology 88, no. 5 (December 2016): 426–32. https://doi.org/10.1212/wnl.0000000000003556.
  30. ^ Cerebral Hypoperfusion and Cognitive Impairment: The Pathogenic Role of Vascular Oxidative Stress International Journal of Neuroscience 122, no. 9 (May 2012): 494–99. https://doi.org/10.3109/00207454.2012.686543.
  31. ^ The Glymphatic System in Central Nervous System Health and Disease: Past, Present, and Future Annual Review of Pathology: Mechanisms of Disease 13, no. 1 (January 2018): 379–94. https://doi.org/10.1146/annurev-pathol-051217-111018.
  32. ^ Glymphatic System Impairment in Alzheimer’s Disease and Idiopathic Normal Pressure Hydrocephalus Trends in Molecular Medicine 26, no. 3 (March 2020): 285–95. https://doi.org/10.1016/j.molmed.2019.11.008.
  33. ^ Lacunar Syndromes, Lacunar Infarcts, and Cerebral Small-vessel Disease Stroke In , 449–65.e4. Elsevier, 2016. https://doi.org/10.1016/b978-0-323-29544-4.00027-x.
  34. ^ Large Virchow-Robin spaces: MR-clinical correlation AJNR Am J Neuroradiol 10, no. 5 (1989): 929–36.
  35. ^ Virchow Robin space dilatation may predict resistance to antidepressant monotherapy in elderly patients with depression Journal of Affective Disorders 97, no. 1-3 (January 2007): 265–70. https://doi.org/10.1016/j.jad.2006.06.024.
  36. ^ DOI: ​​10.1136/jnnp.2003.030858
  37. ^ Cognitive Ability and Brain Structure in Type 1 Diabetes Diabetes 52, no. 1 (January 2003): 149–56. https://doi.org/10.2337/diabetes.52.1.149.
  38. ^ The role of brain perivascular space burden in early-stage Parkinson’s disease npj Parkinson s Disease 7, no. 1 (February 2021). https://doi.org/10.1038/s41531-021-00155-0.
  39. ^ Sleep Facilitates Clearance of Metabolites from the Brain: Glymphatic Function in Aging and Neurodegenerative Diseases Rejuvenation Research 16, no. 6 (December 2013): 518–23. https://doi.org/10.1089/rej.2013.1530.
  40. ^ Cerebral Perfusion is Associated With White Matter Hyperintensities in Older Adults With Heart Failure Congestive Heart Failure 19, no. 4 (March 2013): E29–E34. https://doi.org/10.1111/chf.12025.
  41. ^ DOI: ​​10.1001/archpsyc.59.9.785
  42. ^ What are White Matter Hyperintensities Made of? Journal of the American Heart Association 4, no. 6 (June 2015). https://doi.org/10.1161/jaha.114.001140.
  43. ^ A hitchhiker s guide to diffusion tensor imaging Frontiers in Neuroscience 7 (2013). https://doi.org/10.3389/fnins.2013.00031.
  44. ^ Visceral obesity relates to deep white matter hyperintensities via inflammation Annals of Neurology 85, no. 2 (January 2019): 194–203. https://doi.org/10.1002/ana.25396.
  45. ^ White matter hyperintensities and chronicity of depression Journal of Psychiatric Research 39, no. 3 (May 2005): 285–93. https://doi.org/10.1016/j.jpsychires.2004.07.004.
  46. ^ DOI: ​​10.3390/ijms22094958
  47. ^ a   b Amyloid -protein and beyond: the path forward in Alzheimer’s disease Current Opinion in Neurobiology 61 (April 2020): 116–24. https://doi.org/10.1016/j.conb.2020.02.003.
  48. ^ The small HDL particle hypothesis of Alzheimer s disease Alzheimer s &thsemicolon Dementia , April 2022. https://doi.org/10.1002/alz.12649.
  49. ^ Effects of omega-3 fatty acid supplementation and exercise on low-density lipoprotein and high-density lipoprotein subfractions Metabolism 53, no. 6 (June 2004): 749–54. https://doi.org/10.1016/j.metabol.2003.12.019.
  50. ^ Omega-3 fatty acids supplementation in Alzheimer s disease: A systematic review Nutritional Neuroscience 21, no. 8 (May 2017): 529–38. https://doi.org/10.1080/1028415x.2017.1321813.
  51. ^ DOI: ​​10.3389/fnagi.2021.682776
  52. ^ DOI: ​​10.1007/s12640-019-00147-2
  53. ^ Polyphenols in Parkinson’s Disease: A Systematic Review of In Vivo Studies Nutrients 10, no. 5 (May 2018): 642. https://doi.org/10.3390/nu10050642.
  54. ^ Polyphenols and Ischemic Stroke: Insight into One of the Best Strategies for Prevention and Treatment Nutrients 13, no. 6 (June 2021): 1967. https://doi.org/10.3390/nu13061967.
  55. ^ DOI: ​​10.3390/nu13061967
  56. ^ CNS small vessel disease Neurology 92, no. 24 (May 2019): 1146–56. https://doi.org/10.1212/wnl.0000000000007654.
  57. ^ DOI: ​​10.3389/fnagi.2021.694982
  58. ^ Risk Factors for -Amyloid Deposition in Healthy Aging JAMA Neurology 70, no. 5 (May 2013): 600. https://doi.org/10.1001/jamaneurol.2013.1342.
  59. ^ DOI: ​​10.1001/jama.2019.10551
  60. ^ Blood-Brain Barrier Permeability Is Regulated by Lipid Transport-Dependent Suppression of Caveolae-Mediated Transcytosis Neuron 94, no. 3 (May 2017): 581–94.e5. https://doi.org/10.1016/j.neuron.2017.03.043.
  61. ^ Mfsd2a-based pharmacological strategies for drug delivery across the blood brain barrier Pharmacological Research 104 (February 2016): 124–31. https://doi.org/10.1016/j.phrs.2015.12.024.
  62. ^ Dietary polyphenols regulate endothelial function and prevent cardiovascular disease Nutrition 31, no. 1 (January 2015): 28–37. https://doi.org/10.1016/j.nut.2014.04.011.
  63. ^ DOI: ​​10.2174/1566524018666180720165055
  64. ^ Small Vessel Disease and Dietary Salt Intake: Cross-Sectional Study and Systematic Review Journal of Stroke and Cerebrovascular Diseases 26, no. 12 (December 2017): 3020–28. https://doi.org/10.1016/j.jstrokecerebrovasdis.2017.08.004.
  65. ^ High dietary glycemic load was associated with the presence and burden of cerebral small vessel diseases in acute ischemic stroke patients Nutrition Research 51 (March 2018): 93–101. https://doi.org/10.1016/j.nutres.2017.12.009.
  66. ^ The Association between Cerebral Small Vessel Disease and the Gut Microbiome: A Cross-Sectional Analysis Journal of Stroke and Cerebrovascular Diseases 30, no. 3 (March 2021): 105568. https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.105568.
  67. ^ Examining the role of gut dysbiosis in cerebral small vessel disease The FASEB Journal 33, no. S1 (April 2019). https://doi.org/10.1096/fasebj.2019.33.1_supplement.688.9.
  68. ^ Linking Long-Term Dietary Patterns with Gut Microbial Enterotypes Science 334, no. 6052 (October 2011): 105–8. https://doi.org/10.1126/science.1208344.
  69. ^ Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson’s disease Molecular Neurodegeneration 16, no. 1 (February 2021). https://doi.org/10.1186/s13024-021-00427-6.

Topics related to Small vessel disease

view all
  • Blood-brain barrier
    The blood-brain barrier comprises the sets of membranes that separate the central nervous system (CNS) and the peripheral circulatory system. This barrier allows passage of nutrients and cell signals from the bloodstream to the CNS while excluding harmful substances.
  • Vitamin D
    Vitamin D is a hormone that plays critical roles in many physiological processes, such as blood pressure regulation, immune function, and cell growth.
  • Salmon roe
    Salmon roe, the internal egg mass found in female salmon, is rich in protein, vitamins, and the omega-3 fatty acids EPA and DHA.
  • Brain-derived neurotrophic factor (BDNF)
    BDNF is a growth factor known for its influence on neuronal health and for its role in mediating the beneficial cognitive effects associated with exercise.